The pso Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the pso Hub cannot guarantee the accuracy of translated content. The pso and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The PsOPsA Hub is supported by educational grants. All educational content is developed independently by SES in collaboration with our expert steering committee, with no input or influence from financial supporters. We would like to express our gratitude to the following companies for their support: • UCB: For website development, launch, and ongoing maintenance. • UCB: For educational content and news updates.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View pso content recommended for you
Visual abstract | A phase IV trial of apremilast in patients with special area involvement in plaque psoriasis (EMBRACE)
The Psoriasis and Psoriatic Arthritis Hub is pleased to present a visual abstract representing key data from the phase IV EMBRACE trial (NCT03774875), which investigated the efficacy and safety of apremilast in patients with plaque psoriasis and involvement of at least one special area (dorsal hand, face, neck or hairline, scalp, nails, genital areas, or palmoplantar areas). This was a randomized, placebo-controlled trial, which compared apremilast 30 mg twice daily for 16 weeks to placebo.1
We have previously published a visual abstract on the use of apremilast in patients with mild-moderate plaque psoriasis (the ADVANCE trial) and an article about the 5-year safety of apremilast in psoriasis and psoriatic arthritis.
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content